| Patient | Satchel Paige |
|---|---|
| Date of birth | 1953-07-07 |
| Identifiers | MRN HR-ML047-SYN; SSN (made up) 000-47-3381 |
| Document date | 2026-10-27 |
| Author | Delphine Whitaker-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Fifteen-week review after an exacerbation and pulmonary rehabilitation. [S]
Mr. Paige returns five weeks after a moderate exacerbation treated at home with prednisone and doxycycline, and five days after finishing pulmonary rehabilitation (twenty sessions). He used his action plan well: he called the clinic the morning his breathing worsened and started treatment that day. He is back to walking to the store and beyond without stopping and uses albuterol about twice a week. He takes his inhaler every morning. He had his vaccines at the wellness visit three weeks ago with only a sore arm. His aortic ultrasound a week ago showed no aneurysm, and his hepatitis C and hepatitis B tests were negative. He asked whether he needs another inhaler after the flare-up. [S]
| Element | Detail |
|---|---|
| Symptoms | CAT 11; mMRC 1 |
| Exacerbations | One moderate, five weeks ago, treated at home; no hospital stay |
| Six-minute walk | 425 m, from 360; lowest saturation 92 percent |
| Mood | PHQ-9 2 |
| Screening results | Aorta 2.4 cm; hepatitis C and B negative |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Usual mild breathlessness on hills; little sputum; no wheeze |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Musculoskeletal | Negative | No muscle aches |
| Psychiatric | Negative | Mood good; PHQ-9 2 |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Albuterol 90 micrograms per inhalation metered-dose inhaler with a spacer, two inhalations every four hours as needed for breathlessness | Two inhalations with a spacer every 4 hours as needed | Respiratory tract route | 2026-07-14 | active | S |
| Umeclidinium 62.5 micrograms with vilanterol 25 micrograms dry powder inhaler (a LAMA with a LABA), one inhalation once a day | One inhalation each morning; a strong, deep breath in | Respiratory tract route | 2026-07-28 | active | S |
| Atorvastatin 20 mg tablet once a day | One tablet each evening | Oral route | 2026-07-14 | active | S |
| Prednisone 40 mg (two 20 mg tablets) by mouth each morning for five days | Two tablets each morning with food for five days | Oral route | 2026-09-22 to 2026-09-26 | completed | S |
| Doxycycline 100 mg capsule by mouth twice a day for five days | One capsule twice a day with a full glass of water, sitting up, for five days | Oral route | 2026-09-22 to 2026-09-26 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-27 | Body height | 191 | cm | S |
| 2026-10-27 | Body weight | 83.4 | kg | S |
| 2026-10-27 | Body mass index (BMI) [Ratio] | 22.9 | kg/m2 | S |
| 2026-10-27 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-10-27 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-10-27 | Heart rate | 76 | /min | S |
| 2026-10-27 | Respiratory rate | 16 | /min | S |
| 2026-10-27 | Body temperature | 36.6 | Cel | S |
| 2026-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-27 | Six minute walk test | 425 | m | Predicted about 520 m for his age, sex and height; lower limit about 400 m | Normal | S |
| 2026-10-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S |
Vital signs recorded on 2026-10-27; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 128/78, pulse 76, oxygen saturation 95 percent on room air |
| Respiratory | Reduced breath sounds; no wheeze or crackles |
| Cardiovascular | Regular rhythm; no edema |
| Inhaler technique | Correct |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness on exertion for about two years, now after one flight of stairs or a block on the level (mMRC 2), with a morning cough and a little clear sputum most days; no chest pain, ankle swelling, orthopnea, wheeze at rest or weight loss; a former smoker of about 30 pack-years; cause under evaluation with spirometry and a pulmonology consultation | resolved | confirmed | R06.09 | S — Synthetic presenting problem anchored to his documented emphysema; superseded when spirometry at the consultation confirmed COPD. |
| Chronic obstructive pulmonary disease, GOLD grade 2 (post-bronchodilator FEV1/FVC 0.58, FEV1 61% predicted by the race-neutral GLI Global equations), GOLD group B (CAT 18, mMRC 2, no exacerbation in the past year); alpha-1 antitrypsin normal; blood eosinophils 0.08 x 10^3/uL; synthetic modern diagnosis linked to his documented emphysema | active | confirmed | J44.9 | S — Synthetic modern diagnosis made at the consultation, anchored to his documented emphysema; its onset and course in the modern episode are synthetic. |
| Former cigarette smoker, about 30 pack-years, stopped eleven years ago on his own; no use since | active | confirmed | Z87.891 | S — Synthetic smoking history: whether he smoked is not documented in the sources read, so the history is synthetic and labeled as such. |
| Hyperlipidemia: LDL 148 mg/dL, HDL 44 and triglycerides 160 at intake; estimated 10-year cardiovascular risk about 18 percent; atorvastatin started by shared decision | active | confirmed | E78.5 | S — Synthetic cardiovascular risk factor anchored to his documented heart trouble; not a claim about his real lipids. |
| Moderate exacerbation of COPD with a viral cold: more breathlessness, more sputum turning green, and wheeze for three days; oxygen saturation 92 percent; no pneumonia on chest X-ray; treated at home with prednisone and doxycycline; recovered | resolved | confirmed | J44.1 | S — Synthetic exacerbation at the sick visit; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Symptoms: CAT and mMRC dyspnea scale | Every visit | Completed today | CAT 11; mMRC 1 |
| Survey | Exacerbations in the past 12 months (moderate and severe) and GOLD group | Every visit | Completed today | One moderate exacerbation in the past year; still group B |
| Examination | Pulse oximetry at rest | Every visit | Completed today | 95 percent on room air |
| Laboratory | Spirometry: post-bronchodilator FEV1/FVC and FEV1 % predicted (race-neutral GLI Global) | At diagnosis, then at least yearly or with a clear change | Up to date | Next spirometry in the summer, a year after diagnosis |
| Laboratory | Blood eosinophil count | At baseline and when an inhaled corticosteroid is considered | Up to date | 0.08 x 10^3/uL at intake; an inhaled corticosteroid considered after the exacerbation and not advised |
| Self-management | Smoking status and cessation support | Every visit | Completed today | Smoke-free |
| Examination | BMI and nutrition | Every visit | Completed today | BMI 22.9; weight steady after the steroid course |
| Medication safety | Inhaler technique, adherence and side effects (dry mouth, urinary retention) | Every visit | Completed today | Correct technique; no missed doses |
| Examination | ECG and cardiovascular risk | At baseline; reassess after exacerbations | Deferred | The ECG that the CMID protocol calls for after an exacerbation was not done at the sick visit. He has had no chest pain or palpitations, and today's ECG is unchanged from intake, so no harm is evident. Corrective action: ECG done today and added to the clinic's exacerbation visit template |
| Referral | Pulmonary rehabilitation | Offer when mMRC is 2 or more, or CAT 10 or more; within three weeks of a hospital discharge for an exacerbation | Completed today | Twenty sessions completed five days ago; maintenance class and home program |
| Examination | Six-minute walk test | At rehabilitation entry and exit, and for oxygen assessment | Completed today | 425 m at rehabilitation exit; lowest saturation 92 percent |
| Examination | Long-term oxygen assessment | When resting PaO2 is 55 mm Hg or less (60 with cor pulmonale or polycythemia) or saturation 88 percent or less, confirmed twice | Not indicated | Saturation 95 percent at rest and 92 percent at its lowest on walking |
| Self-management | Written and spoken COPD action plan | At diagnosis, reviewed after each exacerbation | Completed today | Used well at the exacerbation; reviewed |
| Self-management | Vaccines: influenza, pneumococcal, RSV, COVID-19, Tdap, zoster | Yearly review | Up to date | Influenza, RSV, COVID-19 and the first zoster dose three weeks ago; PCV20 and Tdap at intake; second zoster dose due |
| Imaging | Low-dose CT lung cancer screening | Yearly at 50 to 80 with 20 or more pack-years, while within fifteen years of quitting | Up to date | Next in the summer |
| Medication safety | Statin safety: muscle symptoms | Every visit | Completed today | No muscle aches |
| Survey | Mood (PHQ-9) | At intake and when symptoms change | Completed today | 2, from 5, with item 9 scored 0 |
Goal progress:
Guideline basis: Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement (2023); CMID: Clinical Monitoring Intelligence Database, COPD and hyperlipidemia monographs (2026); Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023); Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020); A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation (LOTT) (2016); Racial Bias in Pulse Oximetry Measurement (2020); Lung Cancer: Screening (2021); Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022); Adult Immunization Schedule by Age (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Review in three months, sooner for a flare. Spirometry and low-dose CT next summer. Second zoster dose in one to five months. Next wellness visit in a year. [S]